WHO IARC Talc Probably Carcinogenic Group 2A

IARC Talc Classification — Key Data
IARC Group	2A — "Probably Carcinogenic"
Reclassification Date	July 2024
Monograph	Volume 136
Experts Convened	29 international scientists
Previous Classification	Group 2B ("Possibly Carcinogenic")
Scope	All forms of talc
MDL Pending Cases	67,115 (March 2026)
2025 Verdicts Total	$2.5+ billion
Largest Single Verdict	$1.5B (Craft v. J&J, Dec 2025)
FDA Asbestos Finding	15% of cosmetic talc products (2018–2022)

Executive Summary

In July 2024, the World Health Organization's International Agency for Research on Cancer (IARC) formally upgraded talc to Group 2A — "probably carcinogenic to humans" through Monograph Volume 136. The reclassification marks a decisive shift: talc no longer requires asbestos contamination to trigger carcinogen status. Twenty-nine international scientists reviewed the totality of epidemiological, animal, and mechanistic evidence and concluded that the carcinogenic hazard applies to all forms of talc, asbestos-containing and non-asbestos-containing alike. Group 2A is the second-highest cancer-risk designation in the IARC system, below only Group 1 ("known carcinogen").

The scientific foundation for the upgrade rests on peer-reviewed research demonstrating direct links between cosmetic talc exposure and mesothelioma in the absence of occupational asbestos contact. A landmark 2023 study published in the Journal of Occupational and Environmental Medicine documented 166 mesothelioma patients with confirmed cosmetic talc exposure; 73.5% had no other identifiable asbestos source, establishing talc as an independent causative agent — not merely a contaminant carrier. FDA testing of cosmetic talc products from 2018 through 2022 detected asbestos in 15% of samples, confirming that consumer products reaching household shelves contained known carcinogens throughout the period when exposure claims arose.

The IARC reclassification has accelerated an already massive litigation wave. As of March 2026, 67,115 cases remain pending in MDL 2738 against Johnson & Johnson. Talc verdicts in 2025 alone exceeded $2.5 billion in total award value, including a $1.5 billion single-plaintiff verdict in Craft v. Johnson & Johnson (Baltimore, December 2025) — the largest award in individual talc litigation history — and a $966 million verdict in Moore v. Johnson & Johnson (Los Angeles, October 2025). Johnson & Johnson's three attempts to discharge talc liability through subsidiary bankruptcy filings have all failed, leaving the company facing direct civil litigation.

Regulatory response to the IARC classification has been uneven. The European Union is moving toward a talc ban in cosmetics scheduled for 2027. In the United States, the FDA withdrew a proposed mandatory asbestos testing rule for talc in December 2025 under the direction of Health and Human Services Secretary RFK Jr., removing the primary federal safeguard that would have required pre-market contamination screening for consumer talc products.

At-a-Glance

• IARC upgraded talc to Group 2A ("probably carcinogenic") in July 2024 via Monograph Volume 136, following review by 29 international experts
• All forms of talc carry the Group 2A classification — not just asbestos-contaminated varieties
• Group 2A is the second-highest IARC carcinogen tier; the upgrade from Group 2B represents a meaningful escalation in evidential weight
• Moline et al. 2023 identified 166 mesothelioma patients with cosmetic talc exposure; 73.5% had no other asbestos source
• FDA asbestos testing found contamination in 15% of cosmetic talc products sampled between 2018 and 2022
• 67,115 cases are pending in MDL 2738 as of March 2026
• $2.5+ billion in talc verdicts were awarded in 2025 alone
• $1.5 billion single-plaintiff verdict in Craft v. J&J (December 2025) is the largest in talc litigation history
• Johnson & Johnson's three bankruptcy attempts have all been rejected; direct civil liability exposure continues
• EU plans to ban talc in cosmetics by 2027; the U.S. FDA withdrew mandatory testing rules in December 2025

Key Facts

Fact	Detail
IARC Classification Date	July 2024 — Monograph Volume 136
IARC Group Assigned	Group 2A — "Probably Carcinogenic to Humans"
Previous Classification	Group 2B — "Possibly Carcinogenic to Humans"
Expert Panel Size	29 international scientists convened by IARC/WHO
Scope of Classification	All forms of talc (not limited to asbestos-contaminated talc)
Primary Cancer Association	Mesothelioma and ovarian cancer
Moline 2023 Key Finding	73.5% of 166 mesothelioma patients with talc exposure had no other asbestos source
FDA Contamination Rate	Asbestos found in 15% of cosmetic talc products tested 2018–2022
MDL 2738 Pending Cases	67,115 as of March 2026
Largest 2025 Verdict	$1.5 billion — Craft v. J&J, Baltimore, December 2025
Second-Largest 2025 Verdict	$966 million — Moore v. J&J, Los Angeles, October 2025
EU Regulatory Action	Talc ban in cosmetics planned for 2027

What Is the IARC Group 2A Classification and Why Does It Matter?

The International Agency for Research on Cancer operates a five-tier classification system for cancer-causing agents. Group 1 contains known human carcinogens — asbestos, benzene, tobacco smoke. Group 2A contains agents that are probably carcinogenic to humans, meaning the evidence from human studies is limited but supported by sufficient evidence in animal studies or strong mechanistic data. Group 2B ("possibly carcinogenic") represents a lower evidential threshold. The upgrade of talc from 2B to 2A in July 2024 reflects a genuine shift in the weight of scientific evidence, not a reclassification.

The 2A designation for talc applies without restriction to all forms of the mineral. IARC's working group of 29 scientists reviewed perineal and occupational exposure data, tumor biology research, and mechanistic studies on talc particle behavior in tissue. The conclusion: talc particles cause biological changes — chronic inflammation, oxidative stress, and cellular disruption — that independently promote carcinogenesis. Asbestos contamination amplifies risk but is not a prerequisite for it.

For mesothelioma victims and their families, the Group 2A classification carries direct legal weight. Plaintiffs' attorneys use IARC classifications as authoritative scientific evidence in jury trials. Courts treat IARC monographs as admissible expert opinion. The upgrade from 2B to 2A strengthens causation arguments in talc-mesothelioma cases where defendants previously argued that talc itself — absent asbestos — lacked sufficient carcinogenic evidence to support a verdict.

What Evidence Led IARC to Reclassify Talc?

Three categories of evidence drove the 2024 reclassification. First, the epidemiological record: multiple cohort and case-control studies documented elevated mesothelioma risk in individuals with cosmetic talc exposure and no occupational asbestos history. The body of human data, while not individually definitive, met the threshold for "limited evidence" in humans under IARC criteria — and in combination with animal and mechanistic evidence, supported Group 2A designation.

Second, Moline et al. 2023 provided the most direct evidence to date. The study reviewed 166 confirmed mesothelioma patients with documented cosmetic talc exposure. Of those, 73.5% had no other identifiable asbestos exposure pathway — no occupational contact, no secondary household exposure, no neighborhood proximity to asbestos sources. The mesotheliomas were attributable to talc alone. The National Cancer Institute recognizes mesothelioma as a cancer with very limited exposure pathways; the presence of mesothelioma absent other asbestos sources is itself mechanistically significant.

Third, FDA contamination surveillance documented that asbestos in cosmetic talc was not a historical artifact but a present-tense consumer safety problem. The FDA's testing program from 2018 through 2022 found asbestos in 15% of sampled products — demonstrating ongoing exposure risk for consumers who purchased and used products during that window, years after the industry's claimed adoption of better sourcing practices. ATSDR data on asbestos health effects confirms that there is no established safe level of asbestos exposure; any detectable contamination in a consumer product presents measurable cancer risk.

How Does the IARC Classification Affect Talc Lawsuits?

The Group 2A classification entered the litigation environment at a moment when talc cases were already producing historic verdicts. The scientific upgrade removes a key defense argument: that IARC's prior Group 2B designation ("possibly carcinogenic") represented insufficient evidence to establish causation at trial. With 2A on record, plaintiffs can now cite the world's foremost cancer research authority for the proposition that talc probably causes human cancer.

The financial impact is immediate and measurable. 2025 talc verdicts exceeded $2.5 billion in aggregate. The $1.5 billion verdict in Craft v. Johnson & Johnson (Baltimore, December 2025) is the largest single-plaintiff award in the history of talc litigation. The $966 million verdict in Moore v. Johnson & Johnson (Los Angeles, October 2025) represents the second-largest. These verdicts reflect juries' willingness to hold manufacturers accountable under the post-2A scientific consensus.

Johnson & Johnson's response to the litigation has been to attempt liability management through the bankruptcy system. The company created subsidiary entities and filed three separate bankruptcy petitions seeking to channel all talc claims into a bankruptcy trust — a strategy known as the "Texas Two-Step." All three attempts failed. Federal courts rejected the strategy as an improper use of bankruptcy law by a solvent parent company. J&J now faces all 67,115 MDL cases in direct civil litigation, with no bankruptcy shield available.

What Is MDL 2738 and How Many Cases Are Pending?

MDL 2738 is the Multi-District Litigation docket in the U.S. District Court for the District of New Jersey consolidating federal talc claims against Johnson & Johnson. As of March 2026, 67,115 cases are pending in MDL 2738 — making it one of the largest active mass tort dockets in the United States federal court system.

MDL consolidation coordinates pretrial proceedings — discovery, expert witness challenges, and bellwether trials — across thousands of individual cases filed in different jurisdictions. Each plaintiff retains an individual case; MDL does not merge claims into a class action. Bellwether trials in MDL 2738 have produced verdicts that inform both sides' settlement calculations and trial strategy. The size of the docket — growing throughout 2024 and 2025 — reflects the direct effect of the IARC reclassification on plaintiff filing rates: new diagnoses of mesothelioma and ovarian cancer in cosmetic talc users generated new cases at an accelerating pace following the July 2024 upgrade.

What Did the FDA Find When It Tested Talc Products?

The FDA conducted a systematic testing program for asbestos contamination in cosmetic talc products between 2018 and 2022. Results: asbestos was detected in 15% of products tested. Products testing positive included talcum powder products marketed for adult and infant use. The FDA announced findings publicly and in multiple cases worked with manufacturers to recall affected products.

The FDA had been developing a mandatory pre-market asbestos testing regulation that would have required manufacturers to screen talc for asbestos contamination before products reached shelves. In December 2025, the FDA withdrew that proposed rule under the direction of HHS Secretary RFK Jr. The withdrawal eliminated the principal proposed federal safeguard against contaminated talc reaching consumers. The EU's 2027 talc ban in cosmetics will create divergent regulatory standards between American and European consumer markets.

For plaintiffs in ongoing litigation, the FDA's testing record establishes that the products defendants sold during the class period contained confirmed carcinogens — documentation that supports both causation and punitive damages arguments at trial.

Who Is at Risk and What Cancers Are Associated with Talc Exposure?

Talc exposure pathways with documented cancer associations include:

Perineal/cosmetic use: Regular use of talcum powder products on the perineal area — a common practice across several decades — is the primary exposure route in mesothelioma and ovarian cancer litigation. Products including Johnson's Baby Powder and Shower to Shower were marketed for this use.

Occupational exposure: Workers in talc mining, milling, and processing facilities face sustained high-level inhalation exposure. Industrial talc workers have higher recorded rates of lung cancer and mesothelioma than the general population. OSHA and NIOSH have identified occupational talc inhalation as a significant workplace hazard.

Inhalation from contaminated products: Any application of a talc product that becomes airborne — applying powder, handling containers, secondary exposure in the household — creates inhalation risk when the product contains asbestos. The FDA's 15% contamination rate for cosmetic products tested 2018–2022 means that a meaningful fraction of products on store shelves during that period contained confirmed carcinogens at time of sale.

Associated cancers: The IARC Group 2A classification covers mesothelioma — the rare cancer of the lining of the lungs, abdomen, and heart most strongly associated with asbestos exposure — as well as ovarian cancer in women with regular perineal talc use.

Frequently Asked Questions

Does the IARC classification mean talc products are banned?

No. IARC classifications are scientific hazard assessments; they do not carry regulatory enforcement authority. IARC determines whether an agent poses a carcinogenic hazard — it does not set exposure limits, issue bans, or mandate product recalls. Regulatory action is left to individual countries and agencies. In the EU, the 2A classification has accelerated a planned talc ban in cosmetics by 2027. In the United States, the FDA withdrew mandatory testing rules in December 2025, leaving enforcement to voluntary manufacturer compliance.

Is asbestos-free talc still dangerous under the 2024 classification?

Yes. IARC's 2024 reclassification explicitly covers all forms of talc, not just asbestos-contaminated varieties. The working group found sufficient evidence that talc particles themselves — independent of asbestos co-exposure — cause biological changes that promote carcinogenesis. This is a critical distinction from the prior Group 2B designation, which was read by some defendants as limited to contaminated talc products.

Can someone who used cosmetic talc products file a mesothelioma lawsuit?

A person diagnosed with mesothelioma who used cosmetic talc products — particularly Johnson's Baby Powder or similar perineal talc products — has potential grounds for a lawsuit. The Moline 2023 study documented 166 such cases with no other asbestos exposure source. Legal eligibility depends on diagnosis, exposure history, and applicable statutes of limitation. Consulting a mesothelioma attorney promptly after diagnosis is critical; statutes of limitation vary by state and begin running from the date of diagnosis or date the plaintiff knew or should have known about the exposure connection.

What happened to Johnson & Johnson's bankruptcy strategy?

Johnson & Johnson filed three separate bankruptcy petitions through subsidiary entities in an attempt to channel all talc liabilities into a bankruptcy trust and halt civil litigation. Federal courts rejected all three attempts. The courts found that the strategy — known as the "Texas Two-Step" — constituted an improper use of bankruptcy protection by a financially solvent parent company. J&J faces all pending civil cases directly, including the 67,115 cases in MDL 2738.

What is the difference between IARC Group 2A and Group 2B?

Group 2B ("possibly carcinogenic") requires limited evidence in humans or sufficient evidence in animals. Group 2A ("probably carcinogenic") requires either limited evidence in humans and sufficient evidence in animals, or adequate mechanistic evidence supporting carcinogenicity. The upgrade from 2B to 2A reflects a higher evidentiary threshold — the scientific case for talc as a human carcinogen is now stronger than the pre-2024 classification acknowledged.

Quick Statistics

• $2.5 billion+ — Total talc verdict value in 2025
• $1.5 billion — Craft v. J&J verdict, Baltimore, December 2025 (largest single-plaintiff talc verdict)
• $966 million — Moore v. J&J verdict, Los Angeles, October 2025
• 67,115 — Active cases in MDL 2738 as of March 2026
• 3 — Number of Johnson & Johnson bankruptcy attempts rejected by courts
• 29 — International scientists on IARC's Volume 136 working group
• 73.5% — Moline 2023 mesothelioma patients with talc exposure and no other asbestos source
• 15% — FDA's asbestos contamination rate in cosmetic talc products, 2018–2022
• 166 — Mesothelioma patients in Moline 2023 with documented cosmetic talc exposure
• 2027 — Year EU plans to implement talc ban in cosmetics

Get Help

Individuals diagnosed with mesothelioma or ovarian cancer following talc product exposure have legal options. The IARC Group 2A reclassification and the 2025 verdict record demonstrate that juries hold manufacturers accountable when evidence supports causation.

Danziger & De Llano is a mesothelioma law firm with extensive experience in talc litigation. The firm represents clients in MDL 2738 and in state court talc cases nationwide. Consultations are free, and cases are handled on contingency — no fees unless there is a recovery. Contact: dandell.com

To find qualified mesothelioma attorneys near your location: mesotheliomalawyersnearme.com

Time limits apply in all talc cases. Statutes of limitation vary by state and begin running from the date of diagnosis. Do not delay in seeking a legal evaluation.

Related Pages

• Mesothelioma Overview
• Asbestos Health Effects
• Johnson & Johnson Talc Lawsuit
• MDL 2738 Talc Litigation
• IARC Carcinogen Classifications
• Talc and Ovarian Cancer
• Asbestos Fiber Types and Potency
• Mesothelioma Causes
• FDA Asbestos Regulations
• Cosmetic Talc Exposure